Equities research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of Pulmatrix stock opened at $1.89 on Thursday. The business has a 50-day moving average of $1.88 and a 200-day moving average of $1.88. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. The business had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- What Investors Need to Know to Beat the Market
- AMD is Down 35%. Now is the Time to Buy the Dip
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Amazon Stands Tall: New Highs Are in Sight
- What Does Downgrade Mean in Investing?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
